Image-based screening for men at high risk for breast cancer: Benefits and drawbacks

Woods, Ryan W.; Salkowski, Lonie R.; Elezaby, Mai; Burnside, Elizabeth S.; Strigel, Roberta M.; Fowler, Amy M.

doi:10.1016/j.clinimag.2019.11.005

Cited by 21 publications

(20 citation statements)

References 75 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most common findings on the ultrasound are irregular, hypoechoic retro-areolar masses that appear spiculated and have variable vascularity, along with mammography often showing similar spiculated and radio-dense irregular retro-areolar masses [ 62 ]. Similar to its use in diagnosis of FeBC, mammograms have a high sensitivity of 92–100% and high specificity of 90–96% in diagnosing MaBC [ 63 ]. However, there is currently no evidence that support screening for asymptomatic men.…”

Section: Introductionmentioning

confidence: 99%

Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment

Zheng

Leone

2022

Journal of Oncology

View full text Add to dashboard Cite

Male breast cancer (MaBC) is a rare clinical entity, which makes up approximately 1% of all breast cancers. However, the incidence of MaBC has been steadily increasing over the past few decades. The risk factors for MaBC include age, black race, family history of breast cancer, genetic mutations, liver cirrhosis, and testicular abnormalities. The majority of patients with MaBC present with painless lumps, and about half of the patients have at least one lymph node involved at the time of diagnosis. The treatment of MaBC models that of female breast cancer (FeBC), but this is mainly due to lack of prospective studies for MaBC patients. The treatment modality includes surgery, adjuvant radiation, endocrine therapy, and chemotherapy. However, there are some distinct features of MaBC, both clinically and molecularly, that may warrant a different clinical approach. Ongoing multinational effort is required, to conduct clinical trials for MaBC, or the inclusion of MaBC patients in FeBC trials, to help clinicians improve care for MaBC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment

Zheng

Leone

2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Evidence is also lacking on breast cancer screening in men with cancer-predisposing BRCA variants, and practice varies 26. In the UK, men with cancer-predisposing BRCA variants are advised to be breast aware, ie, to know how their breasts usually look and feel, and seek medical advice if they notice changes or have any concerns 13.…”

Section: Case Studiesmentioning

confidence: 99%

Care of men with cancer-predisposingBRCAvariants

Horton

Pharoah

Hayward³

et al. 2021

BMJ

View full text Add to dashboard Cite

“…Currently, there are no published guidelines on mammographic screening in people with Klinefelter syndrome. However, the diagnostic performance of mammograms is highly sensitive and specific for male breast cancer and is likely to result in earlier detection of malignancy 19,70 …”

Section: Discussionmentioning

confidence: 99%

Clinical features and prevalence of Klinefelter syndrome in transgender individuals: A systematic review

Liang

Cheung

Nolan

2022

Clinical Endocrinology

View full text Add to dashboard Cite

Objective: Previous studies have suggested a higher prevalence of Klinefelter syndrome amongst transgender individuals. We undertook a systematic review to determine the prevalence of Klinefelter syndrome amongst transgender individuals presumed male at birth and summarize the clinical features and potential treatment implications for individuals with Klinefelter syndrome commencing gender-affirming hormone therapy. Design: Using preferred reporting items for systematic review and meta-analysis guidelines, we searched EMBASE, MEDLINE and the Cochrane Central Register of Controlled Trials (CENTRAL) up to 31 December 2021. All studies reporting on the prevalence or clinical features of transgender individuals with Klinefelter syndrome were included. This study is registered with the International Prospective Register of Systematic Reviews, number CRD42021227916. Results: Our search strategy retrieved 11 cohort studies comprising 1376 transgender individuals. In all, 14 of 1376 (1.02%) individuals were diagnosed with Klinefelter syndrome. Based on the seven studies in which karyotype was undertaken in all individuals, the prevalence is 9/1013 (0.88%; 95% CI, 0.41% −1.68%). Case reports highlight unique treatment considerations in this population, including azoospermia, venous thromboembolism, and monitoring of breast cancer and bone health. Conclusions: Compared to the general population, observational studies document a higher prevalence of Klinefelter syndrome amongst transgender individuals, though underdiagnosis in the general population limits conclusions. Routine karyotype in transgender people initiating gender-affirming hormone therapy is not supported unless clinical features of Klinefelter syndrome, such as small testicular volume, or hypergonadotropic hypogonadism are present. Transgender individuals with Klinefelter syndrome need to manage a unique risk profile if they desire feminizing gender-affirming hormone therapy.

show abstract

Image-based screening for men at high risk for breast cancer: Benefits and drawbacks

Cited by 21 publications

References 75 publications

Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment

Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment

Care of men with cancer-predisposingBRCAvariants

Clinical features and prevalence of Klinefelter syndrome in transgender individuals: A systematic review

Contact Info

Product

Resources

About